



DOI: 10.54448/ijn24304

REVIEW ARTICLE

Relationship between gut microbiota, probiotics, and obesity in the cellular and molecular mechanisms for the activation of regulatory t cells and control of inflammatory processes: a systematic review

Nicoli Donadeli Gomes^{1*®}, Lauana Claudia Sulzbach^{1®}, Ghabriela Parmigiani Biz^{1®}, Ana Clara Moraes Daleffe^{1®}, Naísa Tessing^{1®}, Maria Luiza Palangana^{1®}, Milena Vonsowski^{1®}, Fernando Xavier de Lima^{1®}, Nathan Roberto Cechini^{1®}, João Pedro Rombaldi Costa^{1®}

¹ Integrated University Center. BR 158 Highway, Km 207, Campo Mourão, Paraná, Brazil.

*Corresponding author: Nicoli Donadeli Gomes. Integrated University Center. BR 158 Highway, Km 207, Campo Mourão, Paraná, Brazil.
E-mail: nicolidgomes@gmail.com
DOI: https://doi.org/10.54448/ijn24304
Received: 03-17-2024; Revised: 05-21-2024; Accepted: 06-15-2024; Published: 06-25-2024; IJN-id: e24304
Editor: Idiberto José Zotarelli Filho, MSc., Ph.D., Post-Doctoral.

Abstract

Introduction: Obesity represents a pandemic represented as a long-term chronic imbalance between calorie intake and energy expenditure, resulting in more than 30% of the world's population (over two billion people) being overweight or obese. Studies show that inflammatory cells Treas regulate such as macrophages and T lymphocytes by reducing the production of cytokines IL-6, IL-10, etc., and microRNAs can regulate the gene expression of inflammatory cells. Probiotics have been increasingly studied for modulating the gut microbiota. **Objective:** It was to develop a systematic review to describe the main considerations of the relationship between gut microbiota, probiotics, and obesity, to list the cellular and molecular mechanisms for the activation of regulatory T cells and control of inflammatory processes. Methods: The PRISMA Platform systematic review rules were followed. The search was carried out from March to May 2024 in the Web of Science, Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 122 articles were found, and 40 articles were evaluated in full and 24 were included and developed in the present systematic

review study. Considering the Cochrane tool for risk of bias, the overall assessment resulted in 25 studies with a high risk of bias and 22 studies that did not meet GRADE and AMSTAR-2. Most studies showed homogeneity in their results, with $X^2 = 78.7\% > 50\%$. It was concluded that probiotic therapy proved to be an important strategy associated with a nutritional change to improve the composition of the gut microbiota. In this context, the probiotics L. paracasei shirota, Akkermansia muciniphila, and Lactobacillus reuteri V3401 stand out, which are responsible for reducing inflammatory markers. Modulation of the gut microbiota through physical exercise, type of nutrients, and use of prebiotics, and/or probiotics have a positive effect on reducing inflammatory markers. Some miRNAs have been implicated in the control of body weight gain, glucose homeostasis, insulin resistance, and lipid metabolism, with crosstalk with the gut microbiota. Furthermore, an association was found between *eggerthi* abundance, miR-183-5p В. expression, and adiponectin levels. Expression of miR-15a-5p was found to be associated with H. parainfluenzae abundance and insulin levels.

Keywords: Obesity. Probiotics. Gut microbiota. MicroRNAs. Regulatory T cells. Inflammatory processes.



Introduction

Obesity represents a pandemic represented as a long-term chronic imbalance between calorie intake and energy expenditure, which causes serious comorbidities [1-3]. Obesity is the result of complex and incompletely understood pathological processes, resulting from crosstalk between environmental factors, genetic susceptibility, and epigenetic mechanisms, resulting in more than 30% of the world's population (over two billion people) being overweight or obese [1]. By 2030, it is estimated that more than 60% of the world's population will be overweight or obese [1,2]. Most patients with obesity, who have a BMI above 30 kg/m², present an imbalance in inflammatory mediators induced by excess nutrients is the basis of metainflammation in obesity, which can be mediated by regulatory T cells (Tregs) and microRNAs. Metainflammation in obesity can cause multiple organ dysfunction [3-5].

In this context, studies show that Tregs regulate inflammatory cells such as macrophages and T lymphocytes by reducing the production of cytokines IL-6, IL-10, etc., and microRNAs can regulate the gene expression of inflammatory cells [4-6]. However, it is not yet known how this occurs in obese patients. Therefore, the present study will aim to determine and understand how the behavior and changes that occur in Tregs and microRNAs interfere with the pathophysiological mechanisms of obesity through the action of probiotics on the gut microbiota, to evaluate the possibility of restoring the normal metabolic function ("metabolic regeneration") and, thus, determining the existence of an eventual therapeutic or even preventive potential. The results suggest that probiotics bind to dendritic cells (DC) to stimulate Treg cells, together with microRNAs, to increase the concentration of interleukins (IL-10 and IL-35), TGF-β and upregulate the MHC class II **[3-6]**.

Thus, probiotics have been increasingly studied in terms of modulating the gut microbiota. It is believed that "supplementation with probiotics appears to reduce concentrations of low-density lipoproteins (LDL) and total cholesterol; improve atherogenic indices; improve glycemic control; reduce body weight, waist circumference, BMI and abdominal visceral adipose tissue; to improve body composition, and reduce concentrations of pro-inflammatory markers, such as interleukin 6 (IL-6) and TNF-a [7]. Considering the influence of the microbiota on the genesis and progression of obesity, as well as its consequences, knowledge about the gut microbiota and the mechanism by which its modulation through diet and/or the use of probiotics can act on the host and contribute to the treatment of obesity. obesity is fundamental [3,7].

Added to this, obesity is associated with chronic low-grade inflammation in adipose tissue. The resident immune microenvironment is not only responsible for maintaining homeostasis in adipose tissue but also plays a crucial role in combating obesity and its comorbidities. Increasing evidence suggests that obesity promotes the activation of resident T cells and macrophages. MicroRNAs contribute to the maintenance of the immune response and obesity in adipose tissue. Resident T cells, macrophages, and adipocytes secrete various miRNAs and communicate with other cells to create a potential effect on metabolic organ crosstalk. Resident macrophages and T cell-associated miRNAs have a prominent role in regulating obesity by targeting diverse signaling pathways **[8-15]**.

Therefore, the present study developed a systematic review to describe the main considerations of the relationship between gut microbiota, probiotics, and obesity, to list the cellular and molecular mechanisms for the activation of regulatory T cells and control of inflammatory processes.

Methods

Study Design

The present study followed the international systematic review model, following the rules of PRISMA (preferred reporting items for systematic reviews and meta-analysis). Available

at:http://www.prismastatement.org/?AspxAutoDetectC ookieSupport=1. Accessed on: 03/19/2024. The methodological quality standards of AMSTAR-2 (Assessing the methodological quality of systematic reviews) were also followed. Available at: https://amstar.ca/. Accessed on: 03/19/2024.

Data Sources and Research Strategy

The literary search process was carried out from March to May 2024 and was developed based on Web of Science, Scopus, PubMed, Lilacs, Ebsco, Scielo, and Google Scholar, covering scientific articles from various eras to the present. The descriptors (MeSH Terms) were used: "*Obesity. Probiotics. Gut microbiota. MicroRNAs. Regulatory T cells. Inflammatory processes"*, and using the Boolean "and" between the MeSH terms and "or" between historical discoveries.

Study Quality and Risk of Bias

Quality was classified as high, moderate, low, or very low in terms of risk of bias, clarity of comparisons, precision, and consistency of analyses. The most evident emphasis was on systematic review articles or meta-analyses of randomized clinical trials, followed by randomized clinical trials. The low quality of evidence was attributed to case

International Journal of Nutrology, São Paulo, Vol 17, Iss 3, e24304, 2024



reports, editorials, and brief communications, according to the GRADE instrument. The risk of bias was analyzed according to the Cochrane instrument by analyzing the Funnel Plot graph (Sample size versus Effect size), using the Cohen test (d).

Results and Discussion Summary of Findings

A total of 122 articles were found that were subjected to eligibility analysis, with 24 final studies being selected to compose the results of this systematic review. The studies listed were of medium to high quality (Figure 1), considering the level of scientific evidence of studies such as meta-analysis, consensus, randomized clinical, prospective, and observational. The biases did not compromise the scientific basis of the studies. According to the GRADE instrument, most studies showed homogeneity in their results, with $X^2=78.7\%>50\%$. Considering the Cochrane tool for risk of bias, the overall assessment resulted in 25 studies with a high risk of bias and 22 studies that did not meet GRADE and AMSTAR-2.

Figure 1. Selection of articles.



Source: Own authorship.

Figure 2 presents the results of the risk of bias of the studies using the Funnel Plot, showing the calculation of the Effect Size (Magnitude of the difference) using the Cohen Test (d). Precision (sample size) was determined indirectly by the inverse of the standard error (1/Standard Error). This graph had a symmetrical behavior, not suggesting a significant risk of bias, both between studies with a small sample size (lower precision) that are shown at the bottom of the graph and in studies with a large sample size that are presented at the top.

Figure 2. The symmetric funnel plot suggests no risk of

bias among the small sample size studies that are shown at the bottom of the plot. High confidence and high recommendation studies are shown above the graph (n=24 studies).



Source: Own authorship.

Obesity, Probiotics, and Gut Microbiota

The findings regarding the use of probiotics are extremely favorable in terms of modulating microorganisms. Symbiotic supplementation using L. paracasei shirota [16] increased the number of individuals of the genus Lactobacillus, despite reducing the number of the bacteria Akkermansia muciniphila, its anti-inflammatory characteristics. known for Depommier collaborators [17] used pasteurized Akkermansia muciniphila supplementation in their study, significantly reducing the concentration of LPS in plasma, a factor that contributed to combating systemic inflammation. Furthermore, the study found good results in improving insulin sensitivity, a factor that contributes immensely to the pathophysiology of obesity associated with T2DM.

One study administered *Lactobacillus reuteri* V3401, managing to alter the microbiota at the phylum level, increasing the amount of Verrucomicrobia. This change is associated with the reduction of IL-6, an inflammatory cytokine **[18]**. Another way to use symbiotic supplementation was to add it to already-known diets, such as the Low-Calorie Ketogenic Diet **[19]**. The administration of synbiotics did not affect the diversity of the microbiota but showed an increase in the population of Odoribacter and Lachnospira, producers of anti-inflammatory mediators.

Crovesy and collaborators **[20]** demonstrated that the use of probiotics and synbiotics is capable of altering the Firmicutes/Bacteroidetes ratio, in addition to altering the amount of Verrucomicrobia. In the study, the group in which only synbiotics were administered achieved a significant increase in serum glutamine levels, which was associated with increased insulin sensitivity and combating the systemic inflammatory process.



The use of *Bifidobacterium pseudocatenulatum* CECT 7756 as a probiotic achieved good results in modulating the microbiota **[21]**. Significantly increasing the proportion of members of the Rikenellaceae family and the Alistipes genus, reducing inflammation due to the increase in bacteria commonly associated with the lean phenotype, in addition to increasing the level of omentin-1, an anti-inflammatory cytokine.

Another study **[22]** used a prebiotic (inulin) to manipulate the gut microbiota population, achieving an increase in Bifidobacterium, in addition to reducing fecal calprotectin, an important intestinal inflammatory marker, a fact that can be associated with changes in the microbiota.

The use of substances that stimulate the growth of specific microbiota species is also studied, to select the predominant type of microorganism in the intestine and modulate tissue inflammation. In this context, Yahoo and collaborators studied oleoyl ethanolamide and its effect on the species *Akkermansia muciniphila* [23]. The results were significant in terms of increasing the desired species through the use of the compound, in addition to reducing the production of pro-inflammatory cytokines.

Still in this light, another study evaluated the influence of vitamin D supplementation on the gut microbiota **[24]**, showing an increase in the genus Lachnospira and a reduction in the genus Blautia. Despite changes in the microbiota, no significant reduction in inflammation or insulin sensitivity was detected. A study that evaluated pomegranate extract as an intervention obtained better results in terms of modulating the microbiota and inflammation **[25]**. The increase in Bacteroides and the reduction in Parvimonas, Methanobrevibacter, and Methanosphaera, bacteria associated with inflammation, contributed positively to the reduction of the systemic inflammatory process.

Furthermore, studies accumulate evidence that circulating miRNAs are associated with obesity **[26-29]**. Some miRNAs have been implicated in the control of body weight gain, glucose homeostasis, insulin resistance, and lipid metabolism **[30,31]**. Thus, miR-21-5p, miR-103a, and miR-221-3p were found downregulated in blood samples from individuals with obesity in a meta-analysis study **[32]**. Furthermore, miRNAs that were dysregulated in obesity are associated with various metabolic processes such as glucose intolerance, maintenance of pancreatic beta cell mass, adipocyte development and adipose tissue physiology, inflammation pathways, and cardiomyocyte survival **[33,34]**.

Furthermore, an interaction was observed between BMI levels, *B. eggerthii* abundance, and the expression of three miRNAs (miR-130b-3p, miR-185-5p, and miR-

21-5p). *B. eggerthii* is one of the intestinal bacteria that metabolizes phenolic acids, considered beneficial for human health **[35]**. In a recent study, *B. eggerthii* abundance was significantly higher in children with obesity and correlated positively with body fat percentage but negatively with insoluble fiber intake in Mexican children. On the other hand, this bacteria was found to be underrepresented after sleeve gastrectomy surgery **[36]**.

Still in this reasoning, of the three miRNAs associated with the abundance of *B. eggerthii* and BMI levels, miR-185-5p and miR-21-5p were also correlated with the abundance of *D. longicatena*. Furthermore, miR-185-5p has been described to be involved in oxidative stress, obesity, and diabetes mellitus in many studies **[37]**. MiR-185-5p has been identified as a regulator of de novo cholesterol biosynthesis and lowdensity lipoprotein uptake **[30]**.

Added to this, an association was found between *B. eggerthi* abundance, miR-183-5p expression, and adiponectin levels. Previous findings demonstrated that miR-183 can contribute to adipocyte differentiation, adipogenesis, and fat cell development **[31]**. Both gain-of-function and loss-of-function assays showed that miR-183 promoted 3T3-L1 adipocyte differentiation, lipid accumulation, and adipogenesis by increasing the expressions of peroxisome proliferator-activated receptor gamma (PPARγ), alphabinding protein to the CCAAT enhancer (C /EBPa), adiponectin and fatty acid synthase (FAS) **[30]**.

Expression of miR-15a-5p was found to be associated with *H. parainfluenzae* abundance and insulin levels. miR-15a positively regulates insulin biosynthesis by inhibiting the expression of the endogenous uncoupling protein 2 (UCP2) gene, leading to higher ATP levels in islets and improving glucose-stimulated insulin secretion. Furthermore, circulating levels of miR-15a were found to be downregulated before the onset of T2DM and also in individuals with incident T2DM compared to controls **[3,4]**.

Conclusion

It was concluded that probiotic therapy proved to be an important strategy associated with nutritional change to improve the composition of the gut microbiota. In this context, the probiotics *L. paracasei shirota, Akkermansia muciniphila,* and *Lactobacillus reuteri* V3401 stand out, which are responsible for reducing inflammatory markers. Modulation of the gut microbiota through physical exercise, type of nutrients, use of prebiotics, and/or probiotics has a positive effect on reducing inflammatory markers. Some miRNAs have been implicated in the control of body weight gain, glucose homeostasis, insulin resistance, and lipid



metabolism, with crosstalk with the gut microbiota. Furthermore, an association was found between *B. eggerthi* abundance, miR-183-5p expression, and adiponectin levels. Expression of miR-15a-5p was found to be associated with *H. parainfluenzae* abundance and insulin levels.

CRediT

Author contributions: Conceptualization - Nicoli Donadeli Gomes, Lauana Claudia Sulzbach, Ghabriela Parmigiani Biz, Ana Clara Moraes Daleffe, Naísa Tessing, Maria Luiza Palangana, Milena Vonsowski, Fernando Xavier de Lima, Nathan Roberto Cechini, João Pedro Rombaldi Costa; Data curation - Nicoli Donadeli Gomes, Lauana Claudia Sulzbach, Ghabriela Parmigiani Biz, Ana Clara Moraes Daleffe, Naísa Tessing, Maria Luiza Palangana, Milena Vonsowski; Formal Analysis - Nicoli Donadeli Gomes, Lauana Claudia Sulzbach, Ghabriela Parmigiani Biz; Investigation - Ana Clara Moraes Daleffe, Naísa Tessing, Maria Luiza Palangana, Milena Vonsowski, Fernando Xavier de Lima, Nathan Roberto Cechini, João Pedro Rombaldi Costa; Methodology -Milena Vonsowski, Fernando Xavier de Lima, Nathan Roberto Cechini, João Pedro Rombaldi Costa; Project administration - Nicoli Donadeli Gomes, Lauana Claudia Sulzbach; Supervision - Naísa Tessing, Maria Luiza Palangana, Milena Vonsowski, Fernando Xavier de Lima, Nathan Roberto Cechini, João Pedro Rombaldi Costa; Writing - original draft - Nicoli Donadeli Gomes, Lauana Claudia Sulzbach, Ghabriela Parmigiani Biz, Ana Clara Moraes Daleffe, Naísa Tessing, Maria Luiza Palangana, Milena Vonsowski, Fernando Xavier de Lima, Nathan Roberto Cechini, João Pedro Rombaldi Costa; Writing-review & editing- Nicoli Donadeli Gomes, Lauana Claudia Sulzbach, Ghabriela Parmigiani Biz, Ana Clara Moraes Daleffe, Naísa Tessing, Maria Luiza Palangana, Milena Vonsowski, Fernando Xavier de Lima, Nathan Roberto Cechini, João Pedro Rombaldi Costa.

Acknowledgment

Not applicable.

Ethical Approval

Not applicable.

Informed Consent

Not applicable.

Funding

Not applicable. **Data Sharing Statement** No additional data are available.

Conflict of Interest

The authors declare no conflict of interest.

Similarity Check

It was applied by Ithenticate[@].

Peer Review Process

It was performed.

About The License©

The author(s) 2024. The text of this article is open access and licensed under a Creative Commons Attribution 4.0 International License.

References

- WHO World Health Organization. Available at: https://www.sbcbm.org.br/endescola-eobesidade. Accessed: April 2024.
- Costa MAC, Vilela DLS, Fraiz GM, Lopes IL, Coelho AIM, Castro LCV, Martin JGP. Effect of kombucha intake on the gut microbiota and obesity-related comorbidities: A systematic review. Crit Rev Food Sci Nutr. 2023;63(19):3851-3866. doi: 10.1080/10408398.2021.1995321.
- Assmann TS, Cuevas-Sierra A, Riezu-Boj JI, Milagro FI, Martínez JA. Comprehensive Analysis Reveals Novel Interactions between Circulating MicroRNAs and Gut Microbiota Composition in Human Obesity. Int J Mol Sci. 2020 Dec 14;21(24):9509. doi: 10.3390/ijms21249509.
- Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011;12:861–874. doi: 10.1038/nrg3074.
- Butz H., Kinga N., Racz K., Patócs A. Circulating miRNAs as biomarkers for endocrine disorders. J. Endocrinol. Investig. 2016;39:1–10. doi: 10.1007/s40618-015-0316-5.
- Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281– 297. doi: 10.1016/S0092-8674(04)00045-5.
- Gomes AC, de Sousa RGM, Botelho PB, Gomes TLN, Prada PO, Mota JF. The additional effects of a probiotic mix on abdominal adiposity and antioxidant Status: A double-blind, randomized trial: Probiotic Mix and Abdominal Adiposity. Obesity. 2017 Jan;25(1):30–8.
- Maurizi G, Babini L, Della Guardia L. Potential role of microRNAs in the regulation of adipocytes liposecretion and adipose tissue physiology. J. Cell. Physiol. 2018;233:9077–9086. doi: 10.1002/jcp.26523.

International Journal of Nutrology, São Paulo, Vol 17, Iss 3, e24304, 2024



- Lorente-Cebrián S, González-Muniesa P, Milagro FI, Martínez JA. MicroRNAs and other non-coding RNAs in adipose tissue and obesity: Emerging roles as biomarkers and therapeutic targets. Clin. Sci. 2019;133:23–40. doi: 10.1042/CS20180890.
- Belcheva A. MicroRNAs at the epicenter of intestinal homeostasis. BioEssays. 2017;39 doi: 10.1002/bies.201600200.
- **11.** Liu S., Weiner H.L. Control of the gut microbiome by fecal microRNA. Microb. Cell. 2016;3:176–177. doi: 10.15698/mic2016.04.492.
- Nakata K, Sugi Y, Narabayashi H, Kobayakawa T, Nakanishi Y, Tsuda M, Hosono A, Kaminogawa S, Hanazawa S, Takahashi K. Commensal microbiota-induced microRNA modulates intestinal epithelial permeability through the small GTPase ARF4. J. Biol. Chem. 2017;292:15426– 15433. doi: 10.1074/jbc.M117.788596.
- Peck BCE, Mah AT, Pitman WA, Ding S, Lund PK, Sethupathy P. Functional Transcriptomics in Diverse Intestinal Epithelial Cell Types Reveals Robust MicroRNA Sensitivity in Intestinal Stem Cells to Microbial Status. J. Biol. Chem. 2017;292:2586–2600. doi: 10.1074/jbc.M116.770099.
- Landrier JF, Derghal A, Mounien L. MicroRNAs in Obesity and Related Metabolic Disorders. Cells. 2019 Aug 9;8(8):859. doi: 10.3390/cells8080859.
- Rakib A, Kiran S, Mandal M, Singh UP. MicroRNAs: a crossroad that connects obesity to immunity and aging. Immun Ageing. 2022 Dec 14;19(1):64. doi: 10.1186/s12979-022-00320-w.
- Kanazawa A, Aida M, Yoshida Y, Kaga H, Katahira T, Suzuki L, et al. Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study. Nutrients. 2021 Feb;13(2):558.
- Depommier C, Everard A, Druart C, Plovier H, Hul MV, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096–103.
- Tenorio-Jiménez C, Martínez-Ramírez MJ, Castillo-Codes ID, Arraiza-Irigoyen C, Tercero-Lozano M, Camacho J, et al. Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in
- **19.** Adults with Metabolic Syndrome: The PROSIR Study. Nutrients. 2019 Jul;11(8):1761.
- **20.** Gutiérrez_Repiso C, Hernández_García C, García_ Almeida JM, Bellido D, Martín_Núñez GM, Sánchez _Alcoholado L, et al. Effect of Synbiotic

Supplementation in a Very_Low_Calorie Ketogenic Diet on Weight Loss Achievement and Gut Microbiota: A Randomized Controlled Pilot Study. Mol Nutr Food Res. 2019 Oct;63(19):1900167.

- **21.** Crovesy L, El-Bacha T, Rosado EL. Modulation of the gut microbiota by probiotics and symbiotics is associated with changes in serum metabolite profile related to a decrease in inflammation and overall benefits to metabolic health: a double-blind randomized controlled clinical trial in women with obesity. Food Funct. 2021;12(5):2161-70.
- 22. Sanchis-Chordà J, Pulgar EMG del, Carrasco-Luna J, Benítez-Páez A, Sanz Y, Codoñer-Franch P. Bifidobacterium pseudocatenulatum CECT 7765 supplementation improves inflammatory status in insulin-resistant obese children. Eur J Nutr. 2018 Sep;
- **23.** Neyrinck AM, Rodriguez J, Zhang Z, Seethaler B, Sánchez CR, Roumain M, et al. Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebocontrolled trial. Eur J Nutr. 2021 Sep;60(6):3159–70.
- 24. Payahoo L, Khajebishak Y, Alivand MR, Soleimanzade H, Alipour S, Barzegari A, et al. Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. Appetite. 2019 Oct;141:104301. 24. Naderpoor N, Mousa A, Arango LFG, Barrett HL, Nitert MD, Courten B de. Effect of Vitamin D Supplementation on Faecal Microbiota: А Randomised Clinical Trial. Nutrients. 2019 Nov;11(12):2888.
- **25.** González-Sarrías A, Romo-Vaquero M, García-Villalba R, Cortés-Martín A, Selma MV, Espín JC. The Endotoxemia Marker Lipopolysaccharide-Binding Protein is Reduced in Overweight-Obese Subjects Consuming Pomegranate Extract by Modulating the Gut Microbiota: A Randomized Clinical Trial. Mol Nutr Food Res. 2018 Jun;62(11):1800160.
- 26. Virtue AT, McCright SJ, Wright JM, Jimenez MT, Mowel WK, Kotzin J, Joannas L, Basavappa MG, Spencer SP, Clark ML, et al. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. Sci. Transl. Med. 2019;11:eaav1892. doi: 10.1126/scitranslmed.aav1892.
- Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M, Gómez-Ambrosi J, Anglada R, Fernández-Formoso JA, Ricart W, et al. Targeting the circulating

International Journal of Nutrology, São Paulo, Vol 17, Iss 3, e24304, 2024



microRNA signature of obesity. Clin Chem. 2013;59:781–792. doi: 10.1373/clinchem.2012.195776.

- Cui X, You L, Zhu L, Wang X, Zhou Y, Li Y, Wen J, Xia Y, Wang X, Ji C, et al. Change in circulating microRNA profile of obese children indicates future risk of adult diabetes. Metabolism. 2018;78:95–105. doi: 10.1016/j.metabol.2017.09.006.
- **29.** Parr EB, Camera DM, Burke LM, Phillips SM, Coffey VG, Hawley JA. Circulating MicroRNA Responses between 'High' and 'Low' Responders to a 16Wk Diet and Exercise Weight Loss Intervention. PLoS ONE. 2016;11:e0152545. doi: 10.1371/journal.pone.0152545.
- Zhao H, Shen J, Daniel-MacDougall C, Wu X, Chow WH. Plasma MicroRNA signature predicting weight gain among Mexican-American women. Obesity. 2017;25:958–964. doi: 10.1002/oby.21824.
- Yang M, Liu W, Pellicane C, Sahyoun C, Joseph BK, Gallo-Ebert C, Donigan M, Pandya D, Giordano C, Bata A, et al. Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J. Lipid Res. 2013;55:226–238. doi: 10.1194/jlr.M041335.
- **32.** Sedgeman LR, Michell DL, Vickers KC. Integrative roles of microRNAs in lipid metabolism and dyslipidemia. Curr. Opin. Lipidol. 2019;30:165–171. doi: 10.1097/MOL.0000000000000603.
- Villard A, Marchand L, Thivolet C, Rome S. Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. J. Mol. Biomark. Diagn. 2015;6:251. doi: 10.4172/2155-9929.1000251.
- **34.** Vienberg S, Geiger J, Madsen S, Dalgaard LT. MicroRNAs in metabolism. Acta Physiol. 2017;219:346–361. doi: 10.1111/apha.12681.
- Duijvis NW, Moerland PD, Kunne C, Slaman MMW, van Dooren FH, Vogels EW, de Jonge WJ, Meijer SL, Fluiter K, te Velde AA. Inhibition of miR-142-5P ameliorates disease in mouse models of experimental colitis. PLoS ONE. 2017;12:e0185097. doi: 10.1371/journal.pone.0185097.
- **36.** Lopez-Legarrea P, de la Iglesia R, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L, Martínez JA, Zulet MA. Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: The RESMENA randomized controlled trial. Nutr. Metab. 2013;10:22. doi: 10.1186/1743-7075-10-22.

 Medina DA, Pedreros JP, Turiel D, Quezada N, Pimentel F, Escalona A, Garrido D. Distinct patterns in the gut microbiota after surgical or medical therapy in obese patients. PeerJ. 2017;5:e3443. doi: 10.7717/peerj.3443.



https://zotarellifilhoscientificworks.com/